FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003798082> ?p ?o ?g. }

• W2003798082 endingPage "466" @default.
• W2003798082 startingPage "459" @default.
• W2003798082 abstract "Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 24 years. Shortly after their introduction, IVIG products were also found to be effective in the treatment of autoimmune and inflammatory disorders. Over the past 2 decades, the list of diseases where IVIG has a demonstrable beneficial effect has grown rapidly. These include Kawasaki disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating polyneuropathy. Recently, we have described a beneficial effect on the reduction of anti-HLA antibodies with subsequent improvement in transplantation of highly HLA-sensitized patients as well as a potent anti-inflammatory effect that is beneficial in the treatment of antibody-mediated rejection (AMR). These advancements have enabled transplantation of patients previously considered untransplantable. These studies and relevant mechanism(s) of action will be discussed here. Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 24 years. Shortly after their introduction, IVIG products were also found to be effective in the treatment of autoimmune and inflammatory disorders. Over the past 2 decades, the list of diseases where IVIG has a demonstrable beneficial effect has grown rapidly. These include Kawasaki disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating polyneuropathy. Recently, we have described a beneficial effect on the reduction of anti-HLA antibodies with subsequent improvement in transplantation of highly HLA-sensitized patients as well as a potent anti-inflammatory effect that is beneficial in the treatment of antibody-mediated rejection (AMR). These advancements have enabled transplantation of patients previously considered untransplantable. These studies and relevant mechanism(s) of action will be discussed here." @default.
• W2003798082 created "2016-06-24" @default.
• W2003798082 creator A5021487648 @default.
• W2003798082 creator A5036281463 @default.
• W2003798082 creator A5044616722 @default.
• W2003798082 creator A5067740422 @default.
• W2003798082 creator A5076738806 @default.
• W2003798082 date "2006-03-01" @default.
• W2003798082 modified "2023-10-15" @default.
• W2003798082 title "Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients" @default.
• W2003798082 cites W1518010828 @default.
• W2003798082 cites W1964180982 @default.
• W2003798082 cites W1976743028 @default.
• W2003798082 cites W1982528317 @default.
• W2003798082 cites W1985474124 @default.
• W2003798082 cites W1991668324 @default.
• W2003798082 cites W2017511990 @default.
• W2003798082 cites W2021005241 @default.
• W2003798082 cites W2041288261 @default.
• W2003798082 cites W2061152465 @default.
• W2003798082 cites W2065864121 @default.
• W2003798082 cites W2066023848 @default.
• W2003798082 cites W2088370127 @default.
• W2003798082 cites W2089290166 @default.
• W2003798082 cites W2095678963 @default.
• W2003798082 cites W2100381854 @default.
• W2003798082 cites W2124897114 @default.
• W2003798082 cites W2131708234 @default.
• W2003798082 cites W2139077483 @default.
• W2003798082 cites W2144233065 @default.
• W2003798082 cites W2152541651 @default.
• W2003798082 cites W2166277046 @default.
• W2003798082 cites W2167254362 @default.
• W2003798082 cites W2168735100 @default.
• W2003798082 cites W2168870572 @default.
• W2003798082 cites W2170363310 @default.
• W2003798082 cites W2324342306 @default.
• W2003798082 cites W2616639792 @default.
• W2003798082 cites W4241819966 @default.
• W2003798082 cites W4248490933 @default.
• W2003798082 doi "https://doi.org/10.1111/j.1600-6143.2005.01214.x" @default.
• W2003798082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16468954" @default.
• W2003798082 hasPublicationYear "2006" @default.
• W2003798082 type Work @default.
• W2003798082 sameAs 2003798082 @default.
• W2003798082 citedByCount "149" @default.
• W2003798082 countsByYear W20037980822012 @default.
• W2003798082 countsByYear W20037980822013 @default.
• W2003798082 countsByYear W20037980822014 @default.
• W2003798082 countsByYear W20037980822015 @default.
• W2003798082 countsByYear W20037980822016 @default.
• W2003798082 countsByYear W20037980822017 @default.
• W2003798082 countsByYear W20037980822018 @default.
• W2003798082 countsByYear W20037980822019 @default.
• W2003798082 countsByYear W20037980822020 @default.
• W2003798082 countsByYear W20037980822021 @default.
• W2003798082 countsByYear W20037980822022 @default.
• W2003798082 crossrefType "journal-article" @default.
• W2003798082 hasAuthorship W2003798082A5021487648 @default.
• W2003798082 hasAuthorship W2003798082A5036281463 @default.
• W2003798082 hasAuthorship W2003798082A5044616722 @default.
• W2003798082 hasAuthorship W2003798082A5067740422 @default.
• W2003798082 hasAuthorship W2003798082A5076738806 @default.
• W2003798082 hasBestOaLocation W20037980821 @default.
• W2003798082 hasConcept C126322002 @default.
• W2003798082 hasConcept C147483822 @default.
• W2003798082 hasConcept C159654299 @default.
• W2003798082 hasConcept C188280979 @default.
• W2003798082 hasConcept C203014093 @default.
• W2003798082 hasConcept C2776820930 @default.
• W2003798082 hasConcept C2777607303 @default.
• W2003798082 hasConcept C2778105408 @default.
• W2003798082 hasConcept C2778691916 @default.
• W2003798082 hasConcept C2778751314 @default.
• W2003798082 hasConcept C2778842783 @default.
• W2003798082 hasConcept C2779019163 @default.
• W2003798082 hasConcept C2779867792 @default.
• W2003798082 hasConcept C2781423770 @default.
• W2003798082 hasConcept C2911091166 @default.
• W2003798082 hasConcept C71924100 @default.
• W2003798082 hasConcept C8891405 @default.
• W2003798082 hasConceptScore W2003798082C126322002 @default.
• W2003798082 hasConceptScore W2003798082C147483822 @default.
• W2003798082 hasConceptScore W2003798082C159654299 @default.
• W2003798082 hasConceptScore W2003798082C188280979 @default.
• W2003798082 hasConceptScore W2003798082C203014093 @default.
• W2003798082 hasConceptScore W2003798082C2776820930 @default.
• W2003798082 hasConceptScore W2003798082C2777607303 @default.
• W2003798082 hasConceptScore W2003798082C2778105408 @default.
• W2003798082 hasConceptScore W2003798082C2778691916 @default.
• W2003798082 hasConceptScore W2003798082C2778751314 @default.
• W2003798082 hasConceptScore W2003798082C2778842783 @default.
• W2003798082 hasConceptScore W2003798082C2779019163 @default.
• W2003798082 hasConceptScore W2003798082C2779867792 @default.
• W2003798082 hasConceptScore W2003798082C2781423770 @default.
• W2003798082 hasConceptScore W2003798082C2911091166 @default.
• W2003798082 hasConceptScore W2003798082C71924100 @default.
• W2003798082 hasConceptScore W2003798082C8891405 @default.

• next